New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
By · October 24, 2026 · 1 min read
This article was originally published by
Wired
and is republished here under license.
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Leave a Reply